Assyro AI

FDA Orange Book · active-ingredient family

Carboprost tromethamine

Carboprost tromethamine is approved as 1 brand and 13 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:HEMABATE · NDA 017989

1

Brand (NDA)

13

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · injectable

ProductApplicantApplicationTEApproved
HEMABATERLDPFIZERNDA 017989APApproved Prior to Jan 1, 1982

Generic (ANDA) products (13)

ProductApplicantApplicationTEApproved
CARBOPROST TROMETHAMINESOMERSET THERAPS LLCANDA 219529APMay 27, 2026
CARBOPROST TROMETHAMINEMICRO LABSANDA 218013APApr 03, 2024
CARBOPROST TROMETHAMINEANI PHARMSANDA 215901Jan 25, 2024
CARBOPROST TROMETHAMINEGLANDANDA 217657APAug 07, 2023
CARBOPROST TROMETHAMINEONESOURCE SPECIALTYANDA 216897APJul 25, 2023
CARBOPROST TROMETHAMINEALEMBICANDA 217198APJun 15, 2023
CARBOPROST TROMETHAMINEEUGIA PHARMAANDA 216939APMay 25, 2023
CARBOPROST TROMETHAMINESOLA PHARMSANDA 216824APMay 19, 2023
CARBOPROST TROMETHAMINECAPLINANDA 216882APFeb 13, 2023
CARBOPROST TROMETHAMINELONG GROVE PHARMSANDA 214499APAug 09, 2022
CARBOPROST TROMETHAMINEAMNEALANDA 215337APJan 27, 2022
CARBOPROST TROMETHAMINESUNNYANDA 213118APMar 25, 2021
CARBOPROST TROMETHAMINEDR REDDYSANDA 211941APJul 02, 2019

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Carboprost tromethamine — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.